{"id":"tenofovir-lamivudine-raltegravir","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Tenofovir and lamivudine work by competing with the natural building blocks of DNA, thereby preventing the virus from replicating. Raltegravir works by blocking the enzyme integrase, which is essential for the virus to integrate its genetic material into the host cell's DNA.","oneSentence":"Tenofovir and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that block HIV replication by inhibiting viral DNA synthesis. Raltegravir is an integrase strand transfer inhibitor (INSTI) that blocks HIV replication by inhibiting viral integration into the host genome.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:03.229Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of HIV-1 infection in adults and children"},{"name":"Prevention of mother-to-child transmission of HIV"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT06630299","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-08","conditions":"HIV-1-Infection","enrollment":600},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT07080138","phase":"","title":"Research on the Psychological Status of Patients With HIV-1 Infection","status":"NOT_YET_RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-01","conditions":"HIV-1-infection, Anxiety Depression","enrollment":500},{"nctId":"NCT06338826","phase":"PHASE2","title":"Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-02-01","conditions":"HIV Infections, HBV Coinfection","enrollment":140},{"nctId":"NCT04012931","phase":"PHASE2","title":"A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-07-18","conditions":"HIV","enrollment":26},{"nctId":"NCT06037564","phase":"PHASE4","title":"B-free Multistage Trial","status":"ENROLLING_BY_INVITATION","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-11-13","conditions":"HIV, Drug Resistance, Drug Drug Interaction","enrollment":210},{"nctId":"NCT00955968","phase":"PHASE4","title":"IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2010-01-01","conditions":"HIV Infection","enrollment":1653},{"nctId":"NCT03332095","phase":"PHASE1, PHASE2","title":"Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-07-02","conditions":"HIV Infections","enrollment":55},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT01352715","phase":"PHASE3","title":"Study of Options for Second-Line Effective Combination Therapy (SELECT)","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2012-03-13","conditions":"HIV-1 Infection","enrollment":515},{"nctId":"NCT03394196","phase":"NA","title":"RESIST-2: 2nd-line ART for HIV-2 Infection","status":"TERMINATED","sponsor":"University of Washington","startDate":"2018-07-04","conditions":"HIV-2 Infection","enrollment":152},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT02995824","phase":"","title":"Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant Recipients","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2002-01","conditions":"Liver Transplantation, HIV Infections, Antiretroviral Therapy","enrollment":271},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT02150993","phase":"PHASE2, PHASE3","title":"First-Line Treatment for HIV-2","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2016-01-26","conditions":"HIV-2 Infection","enrollment":210},{"nctId":"NCT02116660","phase":"PHASE2","title":"Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-09-03","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT01641367","phase":"PHASE4","title":"A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-02-22","conditions":"HIV-1 Infection","enrollment":545},{"nctId":"NCT02273765","phase":"PHASE3","title":"Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2015-09-11","conditions":"HIV-1 Infection, Tuberculosis","enrollment":460},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT01227824","phase":"PHASE3","title":"A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2010-10-19","conditions":"Infection, Human Immunodeficiency Virus I","enrollment":828},{"nctId":"NCT03256422","phase":"PHASE3","title":"Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2017-09-07","conditions":"HIV Infections","enrollment":640},{"nctId":"NCT01829802","phase":"PHASE4","title":"RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected Patients","status":"UNKNOWN","sponsor":"Pedro Cahn","startDate":"2014-05","conditions":"Chronic Infection With HIV","enrollment":50},{"nctId":"NCT00708162","phase":"PHASE3","title":"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-07","conditions":"HIV Infection","enrollment":724},{"nctId":"NCT01908660","phase":"","title":"Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions","status":"COMPLETED","sponsor":"Valme University Hospital","startDate":"2007-01","conditions":"Human Immunodeficiency Virus, Hepatitis B, Chronic, Hepatitis C, Chronic","enrollment":192},{"nctId":"NCT00100048","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-01","conditions":"HIV Infections, Acquired Immunodeficiency Syndrome","enrollment":206},{"nctId":"NCT01294761","phase":"NA","title":"Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir","status":"COMPLETED","sponsor":"National Center for Global Health and Medicine, Japan","startDate":"2011-02","conditions":"HIV Infections","enrollment":59},{"nctId":"NCT00958100","phase":"PHASE2","title":"Raltegravir Switch for Toxicity or Adverse Events","status":"COMPLETED","sponsor":"Catholic University of the Sacred Heart","startDate":"2009-08","conditions":"HIV/AIDS, Antiretroviral Therapy, HIV Infections","enrollment":40},{"nctId":"NCT01565889","phase":"PHASE1, PHASE2","title":"Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-03","conditions":"Hepatitis C, HIV","enrollment":52},{"nctId":"NCT02219672","phase":"PHASE3","title":"Study on the Impact of Triptolide Woldifiion on HIV-1 Reservoir In Acute HIV-1 Infection","status":"UNKNOWN","sponsor":"Peking Union Medical College","startDate":"2014-07","conditions":"AIDS/HIV PROBLEM","enrollment":18},{"nctId":"NCT00624195","phase":"PHASE2, PHASE3","title":"Clinical Trial of CNS-targeted HAART (CIT2)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2007-03","conditions":"HIV Infections","enrollment":59},{"nctId":"NCT00822315","phase":"PHASE2","title":"Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2009-07","conditions":"HIV Infections, Tuberculosis","enrollment":155},{"nctId":"NCT00666055","phase":"","title":"Sex, Aging and Antiretroviral Pharmacokinetics","status":"COMPLETED","sponsor":"Kristine Patterson, MD","startDate":"2008-03","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT01318096","phase":"NA","title":"Safety and Efficacy of Raltegravir+TDF+3TC in HBV/HIV Co-infected Patients","status":"UNKNOWN","sponsor":"Yunnan AIDS Care Center","startDate":"2011-03","conditions":"HBV Coinfection, HIV Infections","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":125,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tenofovir + lamivudine + raltegravir","genericName":"Tenofovir + lamivudine + raltegravir","companyName":"ANRS, Emerging Infectious Diseases","companyId":"anrs-emerging-infectious-diseases","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tenofovir and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that block HIV replication by inhibiting viral DNA synthesis. Raltegravir is an integrase strand transfer inhibitor (INSTI) that blocks HIV replication by inhibiting viral integration into the host genome. Used for Treatment of HIV-1 infection in adults and children, Prevention of mother-to-child transmission of HIV.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}